Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...

Related Keywords

Timothy Mccarthy ,Ted Raad ,Pulmatrix Inc ,Hc Wainwright Co ,Company Quarterly Reports On Form ,Nasdaq ,Chief Executive Officer ,Allergic Bronchopulmonary Aspergillosis ,Recent Program ,Acute Exacerbations ,Chronic Obstructive Pulmonary Disease ,Cipla Agreement ,At The Market Sales Agreement ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Pulmatrix ,Nc ,